IP Library Granted Patent US 12,527,854
Granted Patent B2
US 12,527,854 · App. 17/616,512 · Granted Jan 20, 2026

Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof

Inventors: Anne Billet (Houilles, FR); Frédéric Schmidt (Vincennes, FR); Ludger Johannes (Courbevoie, FR); Denis Servent (Versailles, FR); Gilles Mourier (Villebon-sur-Yvette, FR); Éric Tartour (Paris, FR); Michael Kay (Salt Lake City, UT); James M. Fulcher (Pasco, WA)
Assignees: INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA); APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS); UNIVERSITE DE PARIS; UNIVERSITY OF UTAH RESEARCH FOUNDATION
A61K39/0283A61K47/6415C07K14/25C07K14/60C07K14/605C12P21/02C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,854
App. No.
17/616,512
Granted
Jan 20, 2026
Kind
B2
Abstract

A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

Claims (27)

1 . A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or a variant thereof by peptide chemical synthesis, comprising the steps of:

a) stepwisely coupling amino acid residues onto a support following an amino acid sequence of the STxB protein or the variant thereof, wherein said amino acid residues comprise α amino-protecting groups and optionally side chain-protecting groups, thereby obtaining a synthetic peptide;

b) deprotecting the synthetic peptide obtained from step a) by removing:

b1) the final α amino-protecting group, and

b2) optionally, the side-chain protecting-groups,

thereby obtaining a deprotected synthetic peptide; and

c) cleaving the deprotected synthetic peptide obtained from step b) from the support, thereby obtaining a free monomer of the STxB protein or the variant thereof, wherein said amino acid sequence of the STxB protein is SEQ ID NO: 2, said variant thereof consists of one of the peptides with amino acid sequence selected from SEQ IDs NO: 1 and 3 to 21,

wherein the monomer of the STxB protein or the variant thereof is produced by peptide chemical synthesis of at least two fragments of said STxB protein or variant thereof, wherein said at least two fragments are ligated to obtain the monomer of the STxB protein or the variant thereof, and wherein said at least two fragments consist of SEQ ID NO: 22 and SEQ ID NO: 23.

2 . The method according to claim 1 , wherein step a) comprises the following sequence of substeps:

a1) removing the α amino-protecting group from the support or from the N-terminal amino acid of the synthetic peptide;

a2) optionally, washing the support;

a3) coupling the next amino acid following an amino acid sequence set forth in SEQ ID NO: 2 in a linear C- to N-terminal direction;

a4) optionally, washing the support;

a5) optionally, capping unreacted amino groups; and

a6) optionally, washing the support.

3 . The method according to claim 2 , wherein:

Substep a3) is reiterated more times and/or is carried out for a longer period of time to couple amino acid residues Cys 4, Thr 12, Thr 21, Asn 35, Leu 36, and Ile 45 with respect to SEQ ID NO: 2 numbering than to couple the other amino acid residues of the STxB protein; and

dipeptides Val 5-Thr 6, Asp 18-Thr 19, Phe 30-Thr 31, Leu 41-Ser 42, and Val 50-Thr 51 with respect to SEQ ID NO: 2 numbering are coupled in substep a3) in a pseudoproline dipeptide form.

4 . The method according to claim 2 , wherein substep a3) is reiterated more times and/or carried out for a longer period of time to couple amino acid residues Cys 4, Thr 12, Thr 21, Asn 35, Leu 36, Leu 39, Ile 45, Cys 57, and Val 65 with respect to SEQ ID NO: 2 numbering than to couple the other amino acid residues of the STxB protein or of the variant thereof.

5 . The method according to claim 2 , wherein substep a3) is reiterated more times and/or carried out for a longer period of time to couple amino acid residues Cys 4, Thr 12, Thr 21, Asn 35, Leu 36, Leu 39, Ile 45, Thr 49, Cys 57, and Val 65 with respect to SEQ ID NO: 2 numbering than to couple the other amino acid residues of the STxB protein or of the variant thereof.

6 . The method according to claim 2 , wherein substep a3) is reiterated more times and/or carried out for a longer period of time to couple amino acid residues Thr 1, Cys 4, Tyr 11, Thr 12, Thr 21, Asn 35, Leu 36, Leu 39, Ile 45, Thr 46, Thr 49, Cys 57, and Val 65 with respect to SEQ ID NO: 2 numbering than to couple the other amino acid residues of the STxB protein or of the variant thereof.

7 . The method according to claim 2 , wherein dipeptides Val 5-Thr 6, Asp 18-Thr 19, Phe 30-Thr 31, Leu 41-Ser 42, Val 50-Thr 51, and Phe 63-Ser 64 with respect to SEQ ID NO: 2 numbering are coupled in substep a3) in a pseudoproline dipeptide form.

8 . The method according to claim 1 , wherein the method further comprises one or more of the steps of:

d) precipitating the free monomer of the STxB protein or of the variant thereof obtained from step c), and optionally air-drying and/or lyophilizing the precipitated STxB protein or the variant thereof,

e) oxidizing the free monomer of the STxB protein or of the variant thereof obtained from step c) or d) under conditions suitable for the formation of an intramolecular disulfide bond between Cys 4 and Cys 57 with respect to SEQ ID NO: 2 numbering.

9 . The method according to claim 1 , wherein the method does not comprise a purification step by chromatography.

10 . A monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof obtained by the method according to claim 1 , wherein dipeptides Val 5-Thr 6, Asp 18-Thr 19, Phe 30-Thr 31, Leu 41-Ser 42, and Val 50-Thr 51 with respite to SEQ ID NO: 2 numbering are coupled in a pseudoproline dipeptide form.

Assignments (4)
LICENSE Recorded Aug 22, 2024
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068750/0639 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jan 11, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 062387/0489 →
CHANGE OF NAME Recorded Jun 20, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060390/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022
From: BILLET, ANNE; SCHMIDT, FRÉDÉRIC; JOHANNES, LUDGER; SERVENT, DENIS; MOURIER, GILLES; TARTOUR, ÉRIC; KAY, MICHAEL
To: INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA); APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS); UNIVERSITE DE PARIS; UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 058993/0304 →
Priority Claims (1)
EP 19305720 · Jun 4, 2019 · regional
Continuity (1)
Related Publication 20220233673A1 · Jul 28, 2022
References Cited (35)
US 20140199379A1 · Tartour · 2014 [cited by examiner]
WO 02060937A1 · 2002 [cited by applicant]
Beddoe et al., “Structure, biological functions and applications of the AB5 toxins.” Trends in biochemical sciences; vol. 35, No. 7; 2010; pp. 411-418. [cited by applicant]
Bhavsar et al., “Manipulation of host-cell pathways by bacterial pathogens.” Nature; vol. 449; No. 7164; Oct. 18, 2007; pp. 827-834. [cited by applicant]
Borgia et al., “Chemical synthesis of proteins.” Trends in biotechnology; vol. 18, No. 6; Jun. 2000; pp. 243-251. [cited by applicant]
Brandal et al., “Shiga Toxin 2a in [cited by applicant]
Chauhan et al., “Biochemical Characterization of In vitro Reconstituted Biologically Active Recombinant Shiga Toxin.” Protein and peptide letters; vol. 26, No. 3; 2019; 1 page, abstract included. [cited by applicant]
Choi et al., “Oral immunization with a shiga toxin B subunit: rotavirus NSP4(90) fusion protein protects mice against gastroenteritis.” Vaccine; vol. 23, No. 44; 2005; pp. 5168-5176. [cited by applicant]
Distler et al., “Shiga Toxin Receptor Gb3Cer/CD77: Tumor-Association and Promising Therapeutic Target in Pancreas and Colon Cancer”; PLoS One. vol. 4, No. 8; Aug. 2009; pp. 1-10. [cited by applicant]
El Alaoui et al., “Shiga Toxin-Mediated Retrograde Delivery of a Topoisomerase I Inhibitor Prodrug.” Angewandte Chemie; vol. 46, No. 34; 2007; pp. 6469-6472. [cited by applicant]
Falguières et al., “Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.” Molecular cancer therapeutics; vol. 7, No. 8; Aug. 2008; pp. 2498-2508. [cited by applicant]
Gupta et al., “Antibodies against recombinant shiga toxin subunit B neutralize shiga toxin toxicity in HeLa cells.” Protein and peptide letters; vol. 17, No. 6; 2010; pp. 774-781. [cited by applicant]
Haicheur et al., “The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.” International immunology; vol. 15, N… [cited by applicant]
Haicheur et al., “The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens” J Immunol; vol. 1… [cited by applicant]
Janssen et al., “In vivo Tumor Targeting Using a Novel Intestinal Pathogen-Based Delivery Approach”, Cancer Res. vol. 66, No. 14, 2006; pp. 7230-7236. [cited by applicant]
Johannes et al., “Retrograde Transport of KDEL-bearing B-fragment of Shiga Toxin”, J Biol Chem; vol. 272, No. 31; Aug. 1, 1997; pp. 19554-19561. [cited by applicant]
Johannes et al.,“Shiga toxins—from cell biology to biomedical applications.” Nature reviews. Microbiology; vol. 8, No. 2; Feb. 2010; pp. 105-116. [cited by applicant]
Kovbasnjuk et al., “The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.” Proceedings of the National Academy of Sciences of the United States of America; vol. 102, No. 52; Dec. … [cited by applicant]
Lee et al., “Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.” European journal of immunology; vol. 28, No. 9; 1998; pp. 2726-2737. [cited by applicant]
Mhidia et al., “Synthesis of Peptide-Protein Conjugates using N-succinimidyl carbamate chemistry.” Bioconjugate chemistry; vol. 21, No. 2; 2010; pp. 219-228. [cited by applicant]
Petsch et al., “Endotoxin removal from protein solutions.” Journal of biotechnology; vol. 76, No. 2-3; 2000; pp. 97-119. [cited by applicant]
Raibaut et al., “Solid Phase Protein Chemical Synthesis.” Topics in current chemistry; vol. 363; 2014; pp. 103-254. [cited by applicant]
Reid et al., “Automated solid-phase peptide synthesis: Use of 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium tetrafluoroborate for coupling of tert-Butyloxycarbonyl amino acids”, Analytical Biochemistry; vol. 200,… [cited by applicant]
Sandvig et al., “Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin.” Physiological reviews; vol. 76, No. 4; Oct. 1996; pp. 949-966. [cited by applicant]
Sandvig et al., “Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum.” Nature; vol. 358, No. 6386; Aug. 6, 1992; pp. 510-512. [cited by applicant]
Sharma et al., “Development of a simple fed-batch process for the high-yield production of recombinant shiga toxin B-chain protein.” Protein and peptide letters; vol. 19, No. 2; 2012; pp. 228-237. [cited by applicant]
Smith et al., “Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells.” Infection and immunity; vol. 71, No. 3; Mar. 2003; pp. 1497… [cited by applicant]
Tesh., “Induction of apoptosis by Shiga toxins.” Future microbiology; vol. 5, No. 3; Mar. 2010; pp. 431-453. [cited by applicant]
Thorpe et al. “Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression.” Infection and immunity; vol. 69, No. 10; Oc… [cited by applicant]
Thorpe et al., “Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells.” Infection and immunity; vol. 67, No. 11; Nov. 1999; pp. 5985-5993. [cited by applicant]
Tsang-Lin et al., “Studies of Coupling Kinetics and Correlation of Reaction Conversions to Color Tests for Solid-Phase Peptide Synthesis of AMG 416 by NMR”, Organic Process Research & Development; vol. 22, No. 8, Jul. 2… [cited by applicant]
Wakelin et al., “Dirty little secrets—endotoxin contamination of recombinant proteins”; Immunol Lett.; vol. 106, No. 1; 2006; pp. 1-7. [cited by applicant]
Whiteside, “Immune responses to malignancies.” The Journal of allergy and clinical immunology; vol. 125, No. 2; 2010; pp. 1-25. [cited by applicant]
Wohr et al., “Pseudo-Prolines as a Solubilizing, Structure-Disrupting Protection Technique in Peptide Synthesis” Journal of the American Chemical Society, vol. 118, No. 39; 1996; pp. 9218-9227. [cited by applicant]
(No author) “Solid Phase Peptide Synthesis”, May 1, 2020 (May 1, 2020), Retrieved from the Internet: URL: https://www.bachem.com/fileadmin/user_upload/pdf/Catalogs_Brochures/Solid_Phase_Peptide_Synthesis.pdf. [cited by applicant]